Kamada Ltd
NASDAQ:KMDA

Watchlist Manager
Kamada Ltd Logo
Kamada Ltd
NASDAQ:KMDA
Watchlist
Price: 5.9 USD 0.85%
Market Cap: 339.2m USD
Have any thoughts about
Kamada Ltd?
Write Note

Kamada Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Kamada Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Kamada Ltd
NASDAQ:KMDA
Accounts Receivables
$16.3m
CAGR 3-Years
-15%
CAGR 5-Years
-7%
CAGR 10-Years
0%
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Accounts Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Urogen Pharma Ltd
NASDAQ:URGN
Accounts Receivables
$22.8m
CAGR 3-Years
43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Entera Bio Ltd
NASDAQ:ENTX
Accounts Receivables
$42k
CAGR 3-Years
-45%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bonus Biogroup Ltd
TASE:BONS
Accounts Receivables
â‚Ş437k
CAGR 3-Years
-33%
CAGR 5-Years
12%
CAGR 10-Years
-9%
Pluri Inc
NASDAQ:PLUR
Accounts Receivables
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Kamada Ltd
Glance View

Market Cap
339.1m USD
Industry
Biotechnology

Kamada Ltd. engages in the development and production of pharmaceutical products. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.

KMDA Intrinsic Value
5.83 USD
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Kamada Ltd's Accounts Receivables?
Accounts Receivables
16.3m USD

Based on the financial report for Sep 30, 2024, Kamada Ltd's Accounts Receivables amounts to 16.3m USD.

What is Kamada Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
0%

Over the last year, the Accounts Receivables growth was -35%. The average annual Accounts Receivables growth rates for Kamada Ltd have been -15% over the past three years , -7% over the past five years .

Back to Top